Form 4: Editas Medicine CSO Sells Shares for Tax Obligations
Insider Transaction Report
Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 713 shares of common stock at $2.1531 per share to cover tax withholding obligations from restricted stock unit vesting.
Summary
- Linda Burkly, EVP, Chief Scientific Officer of Editas Medicine, Inc. (EDIT), reported a sale of common stock.
- The transaction involved the disposition of 713 shares of common stock.
- The shares were sold at a price of $2.1531 per share.
- Following this transaction, Linda Burkly beneficially owns 68,777 shares of common stock.
- The sale was executed on December 3, 2025, under a Rule 10b5-1 plan adopted on July 3, 2023.
- This sale was not a discretionary trade but was necessary to meet tax withholding obligations arising from the vesting of restricted stock units on December 2, 2025.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which is neutral in terms of company sentiment. It does not indicate a change in management's view of the company's prospects.
Future Outlook
NA
Management Comments
- Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.
Industry Context
This is a routine insider transaction for tax purposes and does not reflect broader industry trends or competitive positioning. Such sales are common for executives receiving equity compensation.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and not a reflection of management's discretionary view on the stock.
Key Dates
| Date | Description |
|---|---|
| July 3, 2023 | Date Reporting Person adopted the durable automatic sales instruction plan (Rule 10b5-1 plan). |
| December 2, 2025 | Date restricted stock units vested, triggering tax withholding obligations. |
| December 3, 2025 | Date of the reported transaction (sale of common stock). |
| December 4, 2025 | Date the Form 4 was signed and filed. |
Keywords
Editas Medicine, EDIT, Linda Burkly, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.